Arca
Skip to content
Tools
Tools

Fragile x syndrome

Drug research and approvals for fragile x syndrome: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 15 studies of fragile x syndrome are recruiting on ClinicalTrials.gov, Health Canada has authorized 6 drug trials for it since 2013, and FDA has 0 approved and 29 open orphan designations naming it.

  • Recruiting worldwide: 15
  • Trials authorized in Canada: 6
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting now

Newest posted first, of 15 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Phase 3 3

Phase 2 12 of 20

  • MavoglurantMetabotropic glutamate receptor 5 antagonist
  • MetforminMitochondrial complex I (NADH dehydrogenase) inhibitor
  • AcamprosateGlutamate [NMDA] receptor antagonist
  • BasimglurantMetabotropic glutamate receptor 5 modulator
  • GaboxadolGamma-aminobutyric acid receptor subunit alpha-4/beta3/delta agonist
  • BaclofenGABA-B receptor agonist
  • DonepezilAcetylcholinesterase inhibitor
  • LovastatinHMG-CoA reductase inhibitor
  • MinocyclineBacterial 70S ribosome inhibitor
  • STX107Metabotropic glutamate receptor 5 negative allosteric modulator
  • AripiprazoleDopamine D2 receptor partial agonist
  • OxytocinOxytocin receptor agonist

Phase 1 or earlier 3

  • FlumazenilGABA-A receptor; anion channel allosteric antagonist
  • AZD7325GABA receptor alpha-2 subunit positive allosteric modulator
  • Fenobam

How its trials ended

102 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 24 whose ending is known, 33% met their primary endpoint, 21% missed it and 46% stopped early.

  • Completed, result not reported4241%
  • Ongoing2827%
  • Stopped: other or unclear99%
  • Met its primary endpoint88%
  • Status unknown88%
  • Missed its primary endpoint55%
  • Stopped: lack of efficacy11%
  • Stopped: enrollment or feasibility11%

Trials authorized in Canada

Newest first; search them all in Canada trials
Oct 3, 2023Effect of cannabidiol on anxiety and gabaergic function in individuals with fragile-x syndrome (CANAX)CannabidiolDr Francois CorbinPending
Dec 21, 2022An open-label investigation of the effects of sub-perceptual repeat dosing of psilocybin on the behavioural and cognitive symptoms of fragile x syndrome in…PsilocybinNova Mentis Life Science CorpClosed
Mar 27, 2020Effect of cbd on the gabaergic system in patients with fragile x syndromeCannabidiolDr Francois CorbinPending
Nov 29, 2018A randomized, double-blind, placebo-controlled, multiple-center, efficacy and safety study of ZYN002 administered as a transdermal gel to children and…ZYN002 (cannabidiol)Zynerba PharmaceuticalsPending
Oct 24, 2018A double-blind, placebo-controlled trial of metformin in individuals with fragile x syndrome (fxsMetforminGovernors of The University of AlbertaOngoing
Jun 22, 2018Open study to evaluate the efficacy and safety of metformin in individuals with fragile x syndromeMetforminDr Artuela CakuOngoing

FDA orphan designations

Approved first, then open designations, newest first; 15 of 29
Nov 19, 2025Alkanoylamine derivative selective modulator of a Class A G…Treatment of fragile X syndrome (FXS)GEXVal Inc.Designated
Feb 28, 20253-Chloro-4-fluorophenyl-[4-fluoro-4-[[(5-methylpyrimidin-2-y…Treatment of Fragile X syndromeNeurolixis, Inc.Designated
Nov 19, 2024Small molecule modulator of large conductance,…Treatment of fragile X syndromeServier Pharmaceuticals LLCDesignated
May 14, 2024(R) 3-(5-Dimethylcarbamoyl-pent-1-enyl)-N-(2-hydroxy-1-…Treatment of fragile X syndromeSpinogenix, Inc.Designated
Nov 3, 2022BlarcamesineTreatment of Fragile X syndromeAnavex Life Sciences Corp.Designated
Oct 24, 2022Lisuride MaleateTreatment of Fragile X Syndrome.NeuroVenti Inc.Designated
Jun 16, 2022Replication-incompetent adeno-associated virus serotype 9…Treatment of Fragile X SyndromeCincinnati Children's HospitalDesignated
Jun 15, 2022IbudilastTreatment of Fragile X syndromeHealx LimitedDesignated
May 26, 20224-(3-cyano-6-ethoxyquinolin-2-yl)-N-…Treatment of Fragile X syndrome (FXS)Neuronascent, Inc.Designated
Oct 25, 2021PsilocybinTreatment of Fragile X SyndromeNova Mentis Life Science Corp.Designated
May 10, 2021SulindacTreatment of Fragile X syndromeHealx LimitedDesignated
Mar 28, 2019Alpha tocopherol and ascorbic acidTreatment of Fragile X syndromeGenCo Pharmaceuticals LLCDesignated
Mar 26, 2018ZatolmilastTreatment of Fragile X SyndromeTetra Discovery Partners, Inc.Designated
Oct 3, 2017GaboxadolTreatment of Fragile X syndromeHealx LimitedDesignated
Jun 12, 20175,5-dimethyl-3-[2-(7-methylspiro[2H-benzofuran-3,1'-cyclopro…Treatment of fragile X syndromeAutifony Therapeutics LimitedDesignated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.